875 related articles for article (PubMed ID: 27838698)
1. Validation of a Risk Estimation of Tumor Recurrence After Transplant (RETREAT) Score for Hepatocellular Carcinoma Recurrence After Liver Transplant.
Mehta N; Heimbach J; Harnois DM; Sapisochin G; Dodge JL; Lee D; Burns JM; Sanchez W; Greig PD; Grant DR; Roberts JP; Yao FY
JAMA Oncol; 2017 Apr; 3(4):493-500. PubMed ID: 27838698
[TBL] [Abstract][Full Text] [Related]
2. Validation of the prognostic power of the RETREAT score for hepatocellular carcinoma recurrence using the UNOS database.
Mehta N; Dodge JL; Roberts JP; Yao FY
Am J Transplant; 2018 May; 18(5):1206-1213. PubMed ID: 29068145
[TBL] [Abstract][Full Text] [Related]
3. A novel prognostic nomogram accurately predicts hepatocellular carcinoma recurrence after liver transplantation: analysis of 865 consecutive liver transplant recipients.
Agopian VG; Harlander-Locke M; Zarrinpar A; Kaldas FM; Farmer DG; Yersiz H; Finn RS; Tong M; Hiatt JR; Busuttil RW
J Am Coll Surg; 2015 Apr; 220(4):416-27. PubMed ID: 25690672
[TBL] [Abstract][Full Text] [Related]
4. Homocysteine: A novel prognostic biomarker in liver transplantation for alpha-fetoprotein- negative hepatocellular carcinoma.
Yang M; Tan W; Yang X; Zhuo J; Lin Z; Cen B; Lian Z; Li H; Lu D; Wei X; Zheng S; Xu X
Cancer Biomark; 2020; 29(2):197-206. PubMed ID: 32623388
[TBL] [Abstract][Full Text] [Related]
5. Liver transplantation for HCC: validation of prognostic power of the RETREAT score for recurrence in a UK cohort.
Reddy SHS; Mehta N; Dodge JL; Hakeem AR; Khorsandi SE; Jassem W; Vilca-Melendez H; Cortes-Cerisuelo M; Srinivasan P; Prachalias A; Heneghan MA; Aluvihare V; Suddle A; Miquel R; Rela M; Heaton ND; Menon KV
HPB (Oxford); 2022 May; 24(5):596-605. PubMed ID: 34702624
[TBL] [Abstract][Full Text] [Related]
6. Rate of tumor growth predicts recurrence of hepatocellular carcinoma after liver transplantation in patients beyond Milan or UCSF criteria.
Hanouneh IA; Macaron C; Lopez R; Aucejo F; Zein NN
Transplant Proc; 2011 Dec; 43(10):3813-8. PubMed ID: 22172852
[TBL] [Abstract][Full Text] [Related]
7. Early Detection of Hepatocellular Carcinoma Recurrence in the Posttransplant Population: A Comparison of RETREAT and Cleveland Clinic Florida Scoring System.
Hasan B; Colak Y; Khalid RA; Castillo M; Castaneda D; Tandon K; Shaw JJ; Erim T; Zervos XB; Castro FJ; Al-Khalloufi K
Transplant Proc; 2021; 53(1):193-199. PubMed ID: 33069486
[TBL] [Abstract][Full Text] [Related]
8. R3-AFP score is a new composite tool to refine prediction of hepatocellular carcinoma recurrence after liver transplantation.
Costentin C; Piñero F; Degroote H; Notarpaolo A; Boin IF; Boudjema K; Baccaro C; Podestá LG; Bachellier P; Ettorre GM; Poniachik J; Muscari F; Dibenedetto F; Duque SH; Salame E; Cillo U; Marciano S; Vanlemmens C; Fagiuoli S; Burra P; Van Vlierberghe H; Cherqui D; Lai Q; Silva M; Rubinstein F; Duvoux C;
JHEP Rep; 2022 May; 4(5):100445. PubMed ID: 35360522
[TBL] [Abstract][Full Text] [Related]
9. Development of a Risk Classifier to Predict Tumor Recurrence and Lenvatinib Benefits in Hepatocellular Carcinoma After Liver Transplantation.
Deng Y; Yang J; Chen Y; Wang J; Fu B; Zhang T; Yi S; Yang Y
Transplant Proc; 2023; 55(1):153-163. PubMed ID: 36522222
[TBL] [Abstract][Full Text] [Related]
10. Validation of the AFP model as a predictor of HCC recurrence in patients with viral hepatitis-related cirrhosis who had received a liver transplant for HCC.
Notarpaolo A; Layese R; Magistri P; Gambato M; Colledan M; Magini G; Miglioresi L; Vitale A; Vennarecci G; Ambrosio CD; Burra P; Di Benedetto F; Fagiuoli S; Colasanti M; Maria Ettorre G; Andreoli A; Cillo U; Laurent A; Katsahian S; Audureau E; Roudot-Thoraval F; Duvoux C
J Hepatol; 2017 Mar; 66(3):552-559. PubMed ID: 27899297
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of Patients With Hepatocellular Carcinomas That Do Not Produce α-Fetoprotein.
Agopian VG; Harlander-Locke MP; Markovic D; Zarrinpar A; Kaldas FM; Cheng EY; Yersiz H; Farmer DG; Hiatt JR; Busuttil RW
JAMA Surg; 2017 Jan; 152(1):55-64. PubMed ID: 27706479
[TBL] [Abstract][Full Text] [Related]
12. Development and validation of a REcurrent Liver cAncer Prediction ScorE (RELAPSE) following liver transplantation in patients with hepatocellular carcinoma: Analysis of the US Multicenter HCC Transplant Consortium.
Tran BV; Moris D; Markovic D; Zaribafzadeh H; Henao R; Lai Q; Florman SS; Tabrizian P; Haydel B; Ruiz RM; Klintmalm GB; Lee DD; Taner CB; Hoteit M; Levine MH; Cillo U; Vitale A; Verna EC; Halazun KJ; Tevar AD; Humar A; Chapman WC; Vachharajani N; Aucejo F; Lerut J; Ciccarelli O; Nguyen MH; Melcher ML; Viveiros A; Schaefer B; Hoppe-Lotichius M; Mittler J; Nydam TL; Markmann JF; Rossi M; Mobley C; Ghobrial M; Langnas AN; Carney CA; Berumen J; Schnickel GT; Sudan DL; Hong JC; Rana A; Jones CM; Fishbein TM; Busuttil RW; Barbas AS; Agopian VG
Liver Transpl; 2023 Jul; 29(7):683-697. PubMed ID: 37029083
[TBL] [Abstract][Full Text] [Related]
13. Alpha-fetoprotein level > 1000 ng/mL as an exclusion criterion for liver transplantation in patients with hepatocellular carcinoma meeting the Milan criteria.
Hameed B; Mehta N; Sapisochin G; Roberts JP; Yao FY
Liver Transpl; 2014 Aug; 20(8):945-51. PubMed ID: 24797281
[TBL] [Abstract][Full Text] [Related]
14. Alpha-Fetoprotein Slope >7.5 ng/mL per Month Predicts Microvascular Invasion and Tumor Recurrence After Liver Transplantation for Hepatocellular Carcinoma.
Giard JM; Mehta N; Dodge JL; Roberts JP; Yao FY
Transplantation; 2018 May; 102(5):816-822. PubMed ID: 29505494
[TBL] [Abstract][Full Text] [Related]
15. Dynamic α-Fetoprotein Response and Outcomes After Liver Transplant for Hepatocellular Carcinoma.
Halazun KJ; Rosenblatt RE; Mehta N; Lai Q; Hajifathalian K; Gorgen A; Brar G; Sasaki K; Doyle MBM; Tabrizian P; Agopian VG; Najjar M; Ivanics T; Samstein B; Brown RS; Emond JC; Yao F; Lerut J; Rossi M; Mennini G; Iesari S; Finkenstedt A; Schaefer B; Mittler J; Hoppe-Lotichius M; Quintini C; Aucejo F; Chapman W; Sapisochin G
JAMA Surg; 2021 Jun; 156(6):559-567. PubMed ID: 33950167
[TBL] [Abstract][Full Text] [Related]
16. Metroticket 2.0 Model for Analysis of Competing Risks of Death After Liver Transplantation for Hepatocellular Carcinoma.
Mazzaferro V; Sposito C; Zhou J; Pinna AD; De Carlis L; Fan J; Cescon M; Di Sandro S; Yi-Feng H; Lauterio A; Bongini M; Cucchetti A
Gastroenterology; 2018 Jan; 154(1):128-139. PubMed ID: 28989060
[TBL] [Abstract][Full Text] [Related]
17. Ten-Year Outcomes of Liver Transplant and Downstaging for Hepatocellular Carcinoma.
Tabrizian P; Holzner ML; Mehta N; Halazun K; Agopian VG; Yao F; Busuttil RW; Roberts J; Emond JC; Samstein B; Brown RS; Najjar M; Chapman WC; Doyle MM; Florman SS; Schwartz ME; Llovet JM
JAMA Surg; 2022 Sep; 157(9):779-788. PubMed ID: 35857294
[TBL] [Abstract][Full Text] [Related]
18. National Experience on Down-Staging of Hepatocellular Carcinoma Before Liver Transplant: Influence of Tumor Burden, Alpha-Fetoprotein, and Wait Time.
Mehta N; Dodge JL; Grab JD; Yao FY
Hepatology; 2020 Mar; 71(3):943-954. PubMed ID: 31344273
[TBL] [Abstract][Full Text] [Related]
19. The RETREAT score provides valid predictions regarding hepatocellular carcinoma recurrence after liver transplantation.
Åberg F; Abrahamsson J; Schult A; Bennet W; Rizell M; Sternby-Eilard M
Transpl Int; 2021 Dec; 34(12):2869-2874. PubMed ID: 34779038
[TBL] [Abstract][Full Text] [Related]
20. Liver transplantation for hepatocellular carcinoma: a model including α-fetoprotein improves the performance of Milan criteria.
Duvoux C; Roudot-Thoraval F; Decaens T; Pessione F; Badran H; Piardi T; Francoz C; Compagnon P; Vanlemmens C; Dumortier J; Dharancy S; Gugenheim J; Bernard PH; Adam R; Radenne S; Muscari F; Conti F; Hardwigsen J; Pageaux GP; Chazouillères O; Salame E; Hilleret MN; Lebray P; Abergel A; Debette-Gratien M; Kluger MD; Mallat A; Azoulay D; Cherqui D;
Gastroenterology; 2012 Oct; 143(4):986-94.e3; quiz e14-5. PubMed ID: 22750200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
